Correction to ‘Assessing the dynamic changes in vitiligo: Reliability and validity of the Vitiligo Disease Activity Score (VDAS) and Vitiligo Disease Improvement Score (VDIS)’
{"title":"Correction to ‘Assessing the dynamic changes in vitiligo: Reliability and validity of the Vitiligo Disease Activity Score (VDAS) and Vitiligo Disease Improvement Score (VDIS)’","authors":"","doi":"10.1111/jdv.20364","DOIUrl":null,"url":null,"abstract":"<p>van Geel N, Depaepe L, Vandaele V, Mertens L, Van Causenbroeck J, De Schepper, S, Van Coile L, Van Reempts A, De Vos AS, Papeleu J, Hoorens I, Mertens D, Wolkerstorfer A, Lommerts JE, Speeckaert R. Assessing the dynamic changes in vitiligo: reliability and validity of the vitiligo disease activity score (VDAS) and vitiligo disease improvement score (VDIS). <i>J Eur Acad Dermatol Venereol</i> 2022;36(8):1334–1341. https://doi.org/10.1111/jdv.18134</p><p>In the Results section ‘Raters and participants’, the total body surface affected (range and mean) and name of score was incorrect. This should be a range of 0.01%–35.50% (instead of 0.01%–36.43%) and a median (mean) VESplus (instead of VES) of 1.3% (3.1%) instead of 1.3% (3.2%).</p><p>In the Result section ‘Validity’, paragraph b) (‘Construct validity’), as well as in Tables 1 and 2 (in each hypothesis number 2), the correlation between the overall (median of all raters) VDAS<sub>15</sub> and VDAS<sub>60</sub> and relative percentage worsening (in %) between 2 time points as measured by the VESplus score were incorrect. This should be for VDAS<sub>15</sub> rho = 0.733; 95% CI: 0.596–0.828 (instead of 0.791; 95% CI: 0.675–0.869) and for VDAS<sub>60</sub> rho = 0.751; 95% CI: 0.622–0.840 (instead of 0.795; 95% CI: 0.680–0.871). The correlation between the overall (median of all raters) VDIS<sub>15</sub> and VDIS<sub>60</sub> and the relative percentage improvement (in %) between 2 time points as measured by the VESplus score were incorrect. This should be for VDIS<sub>15</sub> rho = 0.511; 95% CI: 0.307–0.670 (instead of rho = 0.372 CI: 0.135–0.568) and for VDIS<sub>60</sub> rho = 0.610; 95% CI: 0.432–0.743 (instead of rho = 0.486; 95% CI: 0.270–0.656. Additional remark: the terms VDAS<sub>0-15</sub>; VDAS<sub>0-60</sub>; VDIS<sub>0-15</sub> and VDIS<sub>0-60</sub> in Table 1 and 2 can be replaced (mean the same thing) as VDAS<sub>15</sub>; VDAS<sub>60</sub>; VDIS<sub>15</sub> and VDIS<sub>60</sub>.</p><p>We apologize for these errors.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"38 12","pages":"2326"},"PeriodicalIF":8.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20364","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the European Academy of Dermatology and Venereology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jdv.20364","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
van Geel N, Depaepe L, Vandaele V, Mertens L, Van Causenbroeck J, De Schepper, S, Van Coile L, Van Reempts A, De Vos AS, Papeleu J, Hoorens I, Mertens D, Wolkerstorfer A, Lommerts JE, Speeckaert R. Assessing the dynamic changes in vitiligo: reliability and validity of the vitiligo disease activity score (VDAS) and vitiligo disease improvement score (VDIS). J Eur Acad Dermatol Venereol 2022;36(8):1334–1341. https://doi.org/10.1111/jdv.18134
In the Results section ‘Raters and participants’, the total body surface affected (range and mean) and name of score was incorrect. This should be a range of 0.01%–35.50% (instead of 0.01%–36.43%) and a median (mean) VESplus (instead of VES) of 1.3% (3.1%) instead of 1.3% (3.2%).
In the Result section ‘Validity’, paragraph b) (‘Construct validity’), as well as in Tables 1 and 2 (in each hypothesis number 2), the correlation between the overall (median of all raters) VDAS15 and VDAS60 and relative percentage worsening (in %) between 2 time points as measured by the VESplus score were incorrect. This should be for VDAS15 rho = 0.733; 95% CI: 0.596–0.828 (instead of 0.791; 95% CI: 0.675–0.869) and for VDAS60 rho = 0.751; 95% CI: 0.622–0.840 (instead of 0.795; 95% CI: 0.680–0.871). The correlation between the overall (median of all raters) VDIS15 and VDIS60 and the relative percentage improvement (in %) between 2 time points as measured by the VESplus score were incorrect. This should be for VDIS15 rho = 0.511; 95% CI: 0.307–0.670 (instead of rho = 0.372 CI: 0.135–0.568) and for VDIS60 rho = 0.610; 95% CI: 0.432–0.743 (instead of rho = 0.486; 95% CI: 0.270–0.656. Additional remark: the terms VDAS0-15; VDAS0-60; VDIS0-15 and VDIS0-60 in Table 1 and 2 can be replaced (mean the same thing) as VDAS15; VDAS60; VDIS15 and VDIS60.
期刊介绍:
The Journal of the European Academy of Dermatology and Venereology (JEADV) is a publication that focuses on dermatology and venereology. It covers various topics within these fields, including both clinical and basic science subjects. The journal publishes articles in different formats, such as editorials, review articles, practice articles, original papers, short reports, letters to the editor, features, and announcements from the European Academy of Dermatology and Venereology (EADV).
The journal covers a wide range of keywords, including allergy, cancer, clinical medicine, cytokines, dermatology, drug reactions, hair disease, laser therapy, nail disease, oncology, skin cancer, skin disease, therapeutics, tumors, virus infections, and venereology.
The JEADV is indexed and abstracted by various databases and resources, including Abstracts on Hygiene & Communicable Diseases, Academic Search, AgBiotech News & Information, Botanical Pesticides, CAB Abstracts®, Embase, Global Health, InfoTrac, Ingenta Select, MEDLINE/PubMed, Science Citation Index Expanded, and others.